Render Target: STATIC
Render Timestamp: 2024-11-20T11:34:09.211Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-20 06:20:08.092
Product last modified at: 2024-07-29T12:30:10.296Z
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a

Mutant Ras Antibody Sampler Kit #18070

    Product Information

    Kit Usage Information

    Protocols

    Product Description

    The Mutant Ras Antibody Sampler Kit provides an economical means of detecting common mutation in the Ras protein. The kit contains enough primary and secondary antibodies to perform at least two western blot experiments.

    Specificity / Sensitivity

    Each antibody in the Mutant Ras Antibody Sampler kit detects endogenous levels of its target protein. Ras (D2C1) Rabbit mAb recognizes endogenous levels of total Ras protein, specifically K-Ras and N-Ras. This antibody does not cross-react with H-Ras or R-Ras.

    Source / Purification

    Monoclonal antibodies are produced by immunizing rabbits with synthetic peptides corresponding to G12V and G12D mutant sequences of human Ras protein. Ras (D2C1) Rabbit mAb was produced by immunizing rabbits with a recombinant protein specific to human K-Ras protein.

    Background

    The 21 kDa guanine-nucleotide binding proteins (K-Ras, H-Ras, and N-Ras) cycle between active (GTP-bound) and inactive (GDP-bound) forms (1). Receptor tyrosine kinases and G protein-coupled receptors activate Ras, which then stimulates the Raf-MEK-MAPK pathway (2-4). GTPase-activating proteins (GAP) normally facilitate the inactivation of Ras. However, research studies have shown that in 30% of human tumors, point mutations in Ras prevent the GAP-mediated inhibition of this pathway (5). The most common oncogenic Ras mutation found in tumors is Gly12 to Asp12 (G12D), which prevents Ras inactivation, possibly by increasing the overall rigidity of the protein (5,6). Additional oncogenic mutations of Ras have been observed at varying frequencies at codons 12, 13, and 61. The Gly12 to Val12 (G12V) mutation has been detected in a number of different cancers, including colorectal and thyroid cancer (7,8).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.